Skip to content

We are a biopharmaceutical company leveraging antibody engineering to design and develop new precision radiotherapeutics for cancer.

Abdera’s Radio Optimized Vector Engineering (ROVEr™) platform enables the company to engineer potential best-in-class therapies with tunable pharmacokinetic (PK) properties to address a broad range of novel and clinically-validated solid tumor targets. Our company, technology and team are purpose-built to attack cancer.

More on Abdera Therapeutics coming soon